# Therapy of Essential Hypertension With Kinzal®/ Kinzalplus®

> **NCT00927537** · — · COMPLETED · sponsor: **Bayer** · enrollment: 2052 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Telmisartan (Kinzal/Pritor, BAY68-9291)
- **DRUG:** Telmisartan (Kinzal/Pritor, BAY68-9291) + Hydrochlorothiazide

## Key facts

- **NCT ID:** NCT00927537
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 2052 (ACTUAL)
- **Last updated:** 2013-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00927537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00927537, "Therapy of Essential Hypertension With Kinzal®/ Kinzalplus®". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00927537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*